Clinical and Biological Significance of Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Apr 19

PMID 30995757

Citations 8

Authors

Anna Nagel

Jolanta Szade

Mariola Iliszko

Julia Elzanowska

Marzena Welnicka-Jaskiewicz

Jaroslaw Skokowski

Grzegorz Stasilojc

Jacek Bigda

Rafal Sadej

Anna Zaczek

Aleksandra Markiewicz

Affiliations

Soon will be listed here.

Abstract

The amplification of estrogen receptor alpha (ERα) encoded by the gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms-ERα66 and ERα36-on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased gene dosage is not related to gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of isoform ( = 0.01). Interestingly, the short ER isoform was expressed in samples with increased gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to increased gene dosage, high expression was linked with the decreased disease-free survival of the patients ( = 0.05), which was independent of the status of the classical level in breast tumors.

Citing Articles

Hormone-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology.

Miki Y Int J Mol Sci. 2023; 24(13).

PMID: 37446008 PMC: 10341538. DOI: 10.3390/ijms241310830.

14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer.

Garan L, Xiao Y, Lin W Proc Natl Acad Sci U S A. 2022; 119(43):e2209211119.

PMID: 36252018 PMC: 9618134. DOI: 10.1073/pnas.2209211119.

Nuclear hormone receptors in demyelinating diseases.

Zorrilla Veloz R, McKenzie T, Palacios B, Hu J J Neuroendocrinol. 2022; 34(7):e13171.

PMID: 35734821 PMC: 9339486. DOI: 10.1111/jne.13171.

ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer.

Nagel A, Popeda M, Muchlinska A, Sadej R, Szade J, Zielinski J Cancers (Basel). 2022; 14(8).

PMID: 35454913 PMC: 9024776. DOI: 10.3390/cancers14082005.

Role of Persistent Organic Pollutants in Breast Cancer Progression and Identification of Estrogen Receptor Alpha Inhibitors Using In-Silico Mining and Drug-Drug Interaction Network Approaches.

Zainab B, Ayaz Z, Rashid U, Al Farraj D, ALKufeidy R, AlQahtany F Biology (Basel). 2021; 10(7).

PMID: 34356536 PMC: 8301456. DOI: 10.3390/biology10070681.

References

Pagani F, Baralle F . Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004; 5(5):389-96. DOI: 10.1038/nrg1327. View

Wang Z, Zhang X, Shen P, Loggie B, Chang Y, Deuel T . Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005; 336(4):1023-7. DOI: 10.1016/j.bbrc.2005.08.226. View

Wang Z, Zhang X, Shen P, Loggie B, Chang Y, Deuel T . A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A. 2006; 103(24):9063-8. PMC: 1482566. DOI: 10.1073/pnas.0603339103. View

Holst F, Stahl P, Ruiz C, Hellwinkel O, Jehan Z, Wendland M . Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007; 39(5):655-60. DOI: 10.1038/ng2006. View

Lee L, Cao J, Deng H, Chen P, Gatalica Z, Wang Z . ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res. 2008; 28(1B):479-83. PMC: 2610490. View

Lebeau A, Grob T, Holst F, Seyedi-Fazlollahi N, Moch H, Terracciano L . Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J Pathol. 2008; 216(2):151-7. DOI: 10.1002/path.2405. View

Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y . Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci. 2009; 100(6):1012-7. PMC: 11159263. DOI: 10.1111/j.1349-7006.2009.01145.x. View

Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J . Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol. 2009; 27(21):3423-9. PMC: 2717750. DOI: 10.1200/JCO.2008.17.2254. View

Zaczek A, Markiewicz A, Jaskiewicz J, Pienkowski T, Rhone P, Jassem J . Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. Clin Biochem. 2010; 43(10-11):891-8. DOI: 10.1016/j.clinbiochem.2010.04.060. View

10.

Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010; 134(6):907-22. PMC: 3073033. DOI: 10.5858/134.6.907. View

11.

Zhang X, Kang L, Ding L, Vranic S, Gatalica Z, Wang Z . A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 2010; 30(7):770-80. PMC: 3020987. DOI: 10.1038/onc.2010.458. View

12.

Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Rizzo P . Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev. 2010; 36 Suppl 3:S67-71. DOI: 10.1016/S0305-7372(10)70023-2. View

13.

Moelans C, Monsuur H, de Pinth J, Radersma R, de Weger R, van Diest P . ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Cell Oncol (Dordr). 2011; 34(5):489-94. PMC: 3219866. DOI: 10.1007/s13402-011-0045-5. View

14.

Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M . let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer. Mol Med. 2011; 17(11-12):1233-41. PMC: 3321804. DOI: 10.2119/molmed.2010.00225. View

15.

Wallacides A, Chesnel A, Ajj H, Chillet M, Flament S, Dumond H . Estrogens promote proliferation of the seminoma-like TCam-2 cell line through a GPER-dependent ERα36 induction. Mol Cell Endocrinol. 2011; 350(1):61-71. DOI: 10.1016/j.mce.2011.11.021. View

16.

Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Kitamura S . Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol. 2011; 227(1):8-16. DOI: 10.1002/path.3974. View

17.

Chaudhri R, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan B, Schwartz Z . Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36). J Biol Chem. 2012; 287(10):7169-81. PMC: 3293594. DOI: 10.1074/jbc.M111.292946. View

18.

Zhang J, Li G, Li Z, Yu X, Zheng Y, Jin K . Estrogen-independent effects of ER-α36 in ER-negative breast cancer. Steroids. 2012; 77(6):666-73. DOI: 10.1016/j.steroids.2012.02.013. View

19.

Laenkholm A, Knoop A, Ejlertsen B, Rudbeck T, Jensen M, Muller S . ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. Mol Oncol. 2012; 6(4):428-36. PMC: 5528359. DOI: 10.1016/j.molonc.2012.04.003. View

20.

Zaczek A, Markiewicz A, Seroczynska B, Skokowski J, Jaskiewicz J, Pienkowski T . Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer. Oncologist. 2012; 17(10):1246-55. PMC: 3481890. DOI: 10.1634/theoncologist.2012-0023. View